These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21549569)

  • 41. Progresses in the field of drug design to combat tropical protozoan parasitic diseases.
    Liñares GE; Ravaschino EL; Rodriguez JB
    Curr Med Chem; 2006; 13(3):335-60. PubMed ID: 16475941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. State-of-the-art Review on the Antiparasitic Activity of Benzimidazolebased Derivatives: Facing Malaria, Leishmaniasis, and Trypanosomiasis.
    Francesconi V; Rizzo M; Schenone S; Carbone A; Tonelli M
    Curr Med Chem; 2024; 31(15):1955-1982. PubMed ID: 37718524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential Triazole-based Molecules for the Treatment of Neglected Diseases.
    Mantoani SP; de Andrade P; Chierrito TPC; Figueredo AS; Carvalho I
    Curr Med Chem; 2019; 26(23):4403-4434. PubMed ID: 28748757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic Potential of Flavonoid Derivatives for Certain Neglected Tropical Diseases.
    Pone BK; Ferreira EI
    Curr Drug Targets; 2022; 23(7):680-682. PubMed ID: 35264087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leishmaniasis and Chagas Disease - Neglected Tropical Diseases: Treatment Updates.
    Sangenito LS; da Silva Santos V; d'Avila-Levy CM; Branquinha MH; Souza Dos Santos AL; de Oliveira SSC
    Curr Top Med Chem; 2019; 19(3):174-177. PubMed ID: 30950334
    [No Abstract]   [Full Text] [Related]  

  • 46. Computer-Aided Drug Design Using Sesquiterpene Lactones as Sources of New Structures with Potential Activity against Infectious Neglected Diseases.
    Herrera Acevedo C; Scotti L; Feitosa Alves M; Formiga Melo Diniz MF; Scotti MT
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28054952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infectious diseases. Overcoming neglect of kinetoplastid diseases.
    Bilbe G
    Science; 2015 May; 348(6238):974-6. PubMed ID: 26023124
    [No Abstract]   [Full Text] [Related]  

  • 48. The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases.
    Cheuka PM; Mayoka G; Mutai P; Chibale K
    Molecules; 2016 Dec; 22(1):. PubMed ID: 28042865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei.
    Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M
    Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug design for neglected disease in Brazil.
    Giarolla J; Ferreira EI
    Mini Rev Med Chem; 2015; 15(3):220-42. PubMed ID: 25769971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activities of plant extracts from Saudi Arabia against malaria, leishmaniasis, sleeping sickness and Chagas disease.
    Abdel-Sattar E; Maes L; Salama MM
    Phytother Res; 2010 Sep; 24(9):1322-8. PubMed ID: 20127723
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential Drug Targets in the Pentose Phosphate Pathway of Trypanosomatids.
    Loureiro I; Faria J; Santarem N; Smith TK; Tavares J; Cordeiro-da-Silva A
    Curr Med Chem; 2018; 25(39):5239-5265. PubMed ID: 29210635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteasome as a Drug Target in Trypanosomatid Diseases.
    Silva ML; de Santiago-Silva KM; Fabris M; Camargo PG; de Lima Ferreira Bispo M
    Curr Drug Targets; 2023; 24(10):781-789. PubMed ID: 37469152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease.
    Salas JM; Caballero AB; Esteban-Parra GM; Méndez-Arriaga JM
    Curr Med Chem; 2017; 24(25):2796-2806. PubMed ID: 28521698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial peptides for leishmaniasis.
    Cobb SL; Denny PW
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New drugs for the treatment of human parasitic protozoa].
    Dupouy-Camet J
    Parassitologia; 2004 Jun; 46(1-2):81-4. PubMed ID: 15305692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Privileged small molecules against neglected tropical diseases: A perspective from structure activity relationships.
    Abbasi Shiran J; Kaboudin B; Panahi N; Razzaghi-Asl N
    Eur J Med Chem; 2024 May; 271():116396. PubMed ID: 38643671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlling epidemic sleeping sickness.
    Rickman R
    Trends Parasitol; 2002 Feb; 18(2):61-2. PubMed ID: 11832293
    [No Abstract]   [Full Text] [Related]  

  • 59. Leishmaniasis: drugs in the clinic, resistance and new developments.
    Ouellette M; Drummelsmith J; Papadopoulou B
    Drug Resist Updat; 2004; 7(4-5):257-66. PubMed ID: 15533763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trypanosomes at the gates.
    Cross GA
    Science; 2005 Jul; 309(5733):355. PubMed ID: 16020696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.